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Highlights 
 Targeted RNA sequencing assay for body fluid identification tested within 
17 EUROFORGEN / EDNAP laboratories 
 Identification of stains containing blood, semen, saliva, vaginal secretion, 
menstrual blood and skin 
 2 assays containing 33 and 29 biomarkers for Illumina MiSeq/FGx and Ion 
Torrent PGM/S5, respectively 
 Statistical analysis of results using partial least squares analysis (PLS) 
 
Abstract 
In a previous study we presented an assay for targeted mRNA sequencing for the 
identification of human body fluids, optimised for the Illumina MiSeq/FGx MPS 
platform. This assay, together with an additional in-house designed assay for the 
Ion Torrent PGM/S5 platform, formed the basis for a collaborative exercise within 
17 EUROFORGEN and EDNAP laboratories, in order to test the efficacy of 
targeted mRNA sequencing to identify body fluids. The task was to analyse the 
supplied dried body fluid stains and, optionally, participants’ own bona fide or 
mock casework samples of human origin, according to specified protocols. The 
provided primer pools for the Illumina MiSeq/FGx and the Ion Torrent PGM/S5 
platforms included 33 and 29 body fluid specific target sequences, respectively, to 
identify blood, saliva, semen, vaginal secretion, menstrual blood and skin. The 
results demonstrated moderate to high count values in the body fluid or tissue of 
interest with little to no counts in non-target body fluids. There was some inter-
laboratory variability in read counts, but overall the results of the laboratories 
were comparable in that highly expressed markers showed high read counts and 
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less expressed markers lower counts. We performed a partial least squares 
analysis (PLS) on the data, where blood, menstrual blood, saliva and semen 
markers and samples clustered well. The results of this collaborative mRNA 
massively parallel sequencing (MPS) exercise support targeted mRNA 
sequencing as a reliable body fluid identification method that could be added to 
the repertory of forensic MPS panels. 
 
Key words: 
Forensic science, body fluid identification, mRNA profiling, massively parallel 
sequencing 
 
1. Introuction 
Messenger RNA (mRNA) profiling has emerged in the last years as a new 
method for body fluid identification [1-6]. It is based on the premise that each 
single tissue type is comprised of cells that have a unique transcriptome or gene 
expression (i.e. mRNA) profile. A number of markers have been identified for the 
forensically most relevant body fluids and tissues: blood, saliva, semen, vaginal 
secretion, menstrual blood and skin [7-18]. Conventional mRNA profiling includes 
the following steps: RNA extraction, reverse transcription, tissue-specific PCR 
amplification and separation/detection with capillary electrophoresis (CE). The 
main advantages of mRNA profiling compared to conventional protein-based 
methods are a significant improvement in specificity, additional body fluids and 
tissues that can be tested (e.g. menstrual blood, vaginal secretion, nasal 
secretion, skin), the ability of multiplexing numerous mRNA markers for the 
identification of one or several body fluids and the possibility of simultaneously 
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isolating RNA and DNA from the same piece of stain [19, 20]. The co-extraction of 
RNA and DNA allows for positive identification of the tissue/fluid source of origin 
by mRNA profiling as well as a simultaneous identification of the body fluid / 
tissue donor by STR profiling [21]. 
The European DNA Profiling Group (EDNAP – http://www.isfg.org/EDNAP) 
performed six collaborative exercises during the last few years, in order to 
evaluate the robustness and reproducibility of CE-based mRNA profiling for 
blood, saliva, semen, menstrual blood, vaginal secretion and skin identification 
[22-26]. The results of these collaborative exercises support mRNA profiling as a 
reliable body fluid identification method that can easily be combined with current 
STR typing technology. 
The introduction of massively parallel sequencing (MPS) also revolutionised 
transcriptomics. With targeted mRNA sequencing approaches it is possible to 
multiplex numerous markers avoiding time and sample consumption from multiple 
separate analyses. In addition, mRNA sequencing provides a larger dynamic 
range for quantitative analyses and the possibility to identify sequence variation, 
compared to the endpoint PCR/CE-based methods. Furthermore, MPS is 
specifically suitable for degraded samples, since mRNA is usually fragmented 
prior to the reverse transcription step in MPS protocols. Within the 
EUROFORGEN Network of Excellence (https://www.euroforgen.eu) we 
established a targeted mRNA massively parallel sequencing approach for body 
fluid/tissue identification [27]. This included the evaluation of a suitable library 
preparation protocol and sequencing platform, as well as the selection of the 
most appropriate markers, based on the experience with the PCR/CE-system. 
The assay was developed to analyse six different body fluids / tissues, i.e. blood, 
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semen, saliva, vaginal secretion, menstrual blood and skin. In a proof-of-concept-
paper the assay we developed and ran on the Illumina MiSeq/FGx platform was 
demonstrated to identify body fluids with good sensitivity in single source and 
mixed stains [27]. 
Based on this knowledge, a EUROFORGEN / EDNAP collaborative mRNA MPS 
exercise was organised by the Zurich Institute of Forensic Medicine, Switzerland. 
In addition to the Illumina MiSeq/FGx specific assay, we developed a separate 
assay for the Ion Torrent PGM/S5 platform (Ion AmpliSeq™ RNA custom panel, 
Thermo Fisher Scientific, Waltham, MA), enabling laboratories running this 
alternative MPS system to participate in the collaborative exercise. We started 
with a PGM/S5 panel including the same 33 biomarkers that were used for the 
MiSeq/FGx specific assay. Then, in an iterative process, we added new markers 
and removed poorly performing markers (panels 2 and 3 included 61 and 37 
biomarkers, respectively). The final PGM/S5 assay included 29 biomarkers in 
total. In this exercise, either of the two multiplexes was provided to each 
participating laboratory. The exercise included the analysis of 16 and 8 mock 
casework samples for MiSeq/FGx and PGM/S5 users respectively, and optionally 
additional bona fide or mock casework samples from the participating 
laboratories. Here, we present data from the 17 participating laboratories. 
 
2. Materials and methods 
2.1 Samples and materials 
The organising laboratory (Zurich Institute of Forensic Medicine) sent 8 stains to 
laboratories using PGM/S5 (n=9) and 16 stains to laboratories using MiSeq/FGx 
(n=10). Two laboratories performed the experiment on both platforms. Samples 
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were collected from healthy volunteers with their informed consent. The sampling 
was approved by the local ethics commission (KEK), declaration of no objection 
(No. 24-2015). Blood samples were obtained by venipuncture (S-Monovette® 
EDTA, Sarstedt, Nümbrecht, D) and 50 µL were spotted on sterile cotton or 
cellulose swabs. Semen and saliva samples were collected in sterile cups and 
microtubes; respectively and 50 µL each were spotted onto sterile cotton swabs. 
Vaginal secretion and menstrual blood samples were taken using sterile cotton 
swabs from the vagina and 1/4 of a swab was sent to the laboratories. Skin 
samples were collected by rubbing the forearm with a pre-wetted (90% ethanol), 
sterile cotton swab. Mixed samples were produced with different ratios of two 
body fluids. Varying volumes of saliva and semen were spotted on sterile cotton 
swabs containing blood (25 µL), vaginal secretion (1/4 swab), menstrual blood 
(1/4 swab) or skin cells (whole swab). This resulted in a final volume of 50 µL of 
two different body fluids per whole swab or 12.5 µL per 1/4 swab (Table S1). All 
swabs were dried at room temperature for at least 12 hours. 
Laboratories using MiSeq/FGx were asked to analyse 8 additional stains 
containing either human blood, semen, saliva, vaginal secretion, menstrual blood 
or skin or any mixtures thereof, but not more than 2 body fluids/tissues per stain 
(Table S2). 
MiSeq/FGx laboratories used a TruSeq Targeted RNA Expression panel (Illumina 
Inc., San Diego, CA) to amplify the 33 body fluid specific transcripts [27] (Table 
1). PGM/S5 laboratories used an Ion AmpliSeq™ RNA custom panel (Thermo 
Fisher Scientific) detecting 29 body fluid specific transcripts (Table 1). Primer 
pools for both MPS platforms were provided by the organising laboratory. 
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2.2 RNA-extraction and quantification 
Laboratories could use any RNA extraction method of their choice. The 
organising laboratory recommended a manual organic method [1] and a silica 
column based method (RNeasy® Mini Kit, Qiagen, Venlo, NL). For laboratories 
using a PGM/S5, it was highly recommended to use the organic extraction 
method which results in higher RNA yields. We suggested using the TURBO 
DNA-free™ kit (Thermo Fisher Scientific) for DNase treatment. 
To define the desired input amount of RNA, laboratories were advised to quantify 
the RNA extracts using fluorescence or electrophoresis based quantification 
methods. The following methods were recommended: 1) Quant-iT RiboGreen 
RNA kit / Fluorescence microplate reader (high- and low-range protocol options) 
(Thermo Fisher Scientific); 2) QuantiFluor RNA System / QuantiFluor-ST 
Fluorometer (Promega, Madison, WI); 3) Quant-iT RNA assay kit / Qubit 
Fluorometer (Thermo Fisher Scientific); 4) Bioanalyzer (normally bad RNA quality 
/ low RIN numbers with these kind of samples). In case the laboratories had no 
means of quantifying the RNA extracts, the organising laboratory proposed a 
specific input volume for each stain (Table S3). 
 
2.3 Library preparation and sequencing 
The MiSeq/FGx library preparation was performed according to the 
manufacturer’s protocol (#15034665 v01, January 2016) using 50 ng RNA in 3 µL 
and following the “degraded RNA” protocol. Targets were amplified using 34 
cycles. The final library, diluted to 6 pM, was sequenced using 51 cycles single-
read and the MiSeq Reagent Kit v3 (Illumina Inc.). The PGM/S5 library 
preparation was performed according to the manufacturer’s protocol 
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(MAN0007450, Revision A.0) using 50 ng RNA and 30 amplification cycles. 
Pooling and diluting of Ion AmpliSeq™ RNA libraries was recommended as 
follows: for an Ion 314 chip, pooling to 25 pM, resulting in an end concentration of 
4 pM; for Ion 316/318 chips, pooling to 100 pM, resulting in an end concentration 
of 16 pM; for Ion 520/530 chips (S5 sequencing system), pooling to 100 pM, 
resulting in an end concentration of 6.25 pM. 500 flows were used for 
sequencing. 
 
2.4 Data analysis 
Following sequencing, the organising laboratory collected the sequencing raw 
data (fastq/bam files) for further analyses. MiSeq/FGx fastq files were used to run 
the TruSeq Targeted RNA application on BaseSpace cloud (Illumina Inc.), 
resulting in a matrix displaying read counts per amplicon in each sample. 
PGM/S5 bam files were used as input files for the Ion AmpliSeq™ RNA plugin on 
the Torrent Server (Torrent Suite Software v4.6, Thermo Fisher Scientific), 
resulting in an amplicon coverage file. 
 
2.5 Statistical analyses 
To visualise major trends in the data, we performed a partial least squares (PLS) 
analysis. PLS is a decomposition technique similar to principal component 
analysis (PCA). It searches for a small set of orthogonal components, or latent 
variables, that explain as much as possible of the covariance between a set of 
predictor variables and a dependent variable [29]. In this case the predictor 
variables correspond to the mRNA markers, and the dependent variable is the 
body fluid category of each sample. An advantage of using PLS compared to 
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evaluating each mRNA marker separately, is that PLS considers the co-
expression of the markers. Information about mRNA markers that are not 
expressed may be just as valuable as information about markers that are 
expressed, if this is a repeated pattern for samples of that body fluid. 
The PLS analysis requires a normalisation of the data to adjust for different input 
amounts. A centered log-ratio (CLR) transformation [28], commonly used for read 
count data, divides each read count by the read counts sum for the sample, and 
takes the log-ratio of these relative reads. To avoid zero reads, one pseudo count 
was added to each read count. 
R scripts presented here are available from the authors upon request. 
 
3. Results 
3.1 Samples, materials and methods 
Seventeen laboratories participated in the exercise, 10 using the MiSeq/FGx 
platform and 9 using the PGM/S5 platform (2 laboratories did the experiments on 
both platforms). We provided the protocols and primer pools for PGM/S5 and 
MiSeq/FGx to assure conditions were as similar as possible for all laboratories. 
To keep costs reasonable, the smallest possible modular number of samples was 
analysed, which comprised 24 samples for the MiSeq/FGx laboratories (half of a 
TruSeq Targeted RNA Expression Panel Kit) and 8 samples for the PGM/S5 
laboratories (Ion AmpliSeq™ RNA Library Kit). The samples and primers were 
sent at ambient temperature by courier mail. Fifteen laboratories received the 
parcel within 4 days, only one parcel was held back by customs and was in transit 
for 16 days. Two laboratories did not store the primers immediately at -20°C and 
kept them at room temperature for 1-3 weeks. The laboratories were asked to fill 
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in a questionnaire on what methods they used, their quantification results, and 
other relevant information about the experiments conducted (Table S3). Table 2 
shows the RNA extraction and quantification methods used by the participating 
laboratories. As predicted, the manual organic extraction method resulted in 
much higher RNA yields than the inorganic kit-based methods. 
 
3.2 Data analysis 
The final data analysis was performed by the organising laboratory. We identified 
issues with counting reads of some markers using the Ion AmpliSeq™ RNA 
plugin (Figure S1). Usually, only end-to-end reads are considered for the total 
read count of each marker. Figure S1a shows how the amplicons/reads along the 
target sequence are expected to look like when the markers are analysed end-to-
end. Most of the markers were analysed in this manner. The target sequence of 
marker SEMG2 was only partly covered and the end-to-end reads did not 
represent the actual coverage (Figure S1b). For SEMG2, all reads were counted 
although shorter than the target region. For marker MUC7 a lot of short reads 
were aligned to a region adjacent to the actual target region and were wrongly 
counted as target reads (Figure S1c). To remove the non-target short reads, end-
to-end analysis of marker MUC7 was performed. The analysis of MiSeq/FGx data 
did not show any of these issues. 
The results for both marker sets (MiSeq/FGx and PGM/S5) demonstrated 
moderate to high count values in the body fluid or tissue of interest with little or no 
counts in non-target body fluids. Two laboratories (6 and 7) analysed the 8 
samples with the MiSeq/FGx and the PGM/S5 marker set (the same RNA 
extracts were used to produce the respective libraries). Representative 
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MiSeq/FGx and PGM/S5 results from 6 samples (one sample per body fluid) of 
laboratory 6 are shown in Figure 1. Overall the MiSeq/FGx and PGM/S5 results 
were similar in that markers of the target body fluid were highly expressed, some 
markers showed higher reads with the MiSeq/FGx or PGM/S5 assay. This is most 
likely a result of different primer design, PCR efficiency and existing isoforms. 
Non-specific reads were covered on average 1650x for MiSeq/FGx and 1945x for 
PGM/S5. 
In Figure 2 the read counts of the laboratories are compared (MiSeq/FGx 
laboratories 1-7, PGM/S5 laboratories 6, 7, 10-16). Three MiSeq/FGx laboratories 
(laboratories 8, 9 and 17) had no or only a few specific reads and/or some non-
specific reads. Interestingly, these included the two laboratories not using the RT 
enzyme that was recommended in the library preparation protocol. Results from 
laboratories 8, 9 and 17 were therefore omitted from further analyses. All results 
of the PGM/S5 laboratories could be included in downstream analyses. There 
was some inter-laboratory variability in read counts, but overall the results of the 
laboratories were consistent, in that highly expressed markers showed high and 
less expressed markers lower read counts. For PGM/S5 the detection of the low-
level RNA stains (blood and semen) worked only for the laboratories that used a 
manual organic extraction method, where the required RNA input of 50 ng was 
achieved. 
As shown in Figures 1 and 2, variability could also be observed among markers 
within a body fluid / tissue. Results from the MiSeq/FGx assay showed highest 
reads from ALAS2 and AMICA1 for blood samples, from PRM1 and PRM2 for 
semen samples and from HTN3 for saliva samples. Corresponding results from 
samples analysed with the PGM/S5 assay were difficult to interpret for the low-
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level RNA stains blood and semen. For saliva samples, STATH and MUC7 were 
highly expressed. HTN3 was – in contrast to the MiSeq/FGx assay – the least 
expressed marker, probably due to unfavourable primer- or marker design. 
FAM83D and MMP10 were the most prominent markers in both panels for vaginal 
secretion and menstrual blood, respectively. Skin markers were observed only 
sporadically and only with the MiSeq/FGx assay. 
 
3.3 Body fluid inference 
Raw read counts were used to calculate mean percent contributions of all six 
body fluid categories for the analysed stains (Table 3). Samples with < 5000 total 
reads were excluded. All blood, semen, vaginal secretion, menstrual blood and 
skin samples showed expected contributions and were correctly identified with 
both the MiSeq/FGx and the PGM/S5 assay. For saliva samples, moderate 
contributions from vaginal secretion markers could be observed and the 
identification was therefore inconclusive. All four mixed samples were correctly 
identified. 
 
3.4 Statistical analyses 
We performed a partial least squares (PLS) analysis on both the MiSeq/FGx and 
the PGM/S5 data to be able to visualise and compare any major trends in the two 
data sets. The plots in Figure 3 show the correlation between the markers and the 
first four PLS components, and how the body fluid specific markers correlate with 
the respective body fluid categories in the MiSeq/FGx and PGM/S5 data. The 
further the markers are away from the origin, the more influential they are on the 
components. The saliva markers form a clear cluster in the MiSeq/FGx data, and 
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they are also closely correlated with the saliva samples. The same can be 
observed for the semen markers and semen samples. Components 3 and 4 
seem to be more influenced by the vaginal secretion markers as they are further 
away from the origin compared to components 1 and 2. For the PGM/S5 data the 
saliva markers are slightly more scattered for components 1 and 2 compared to 
the MiSeq/FGx data, while the semen samples are not as strongly correlated with 
the semen markers. The skin and vaginal markers are closer to the origin, and 
hence are less influential on these components. The menstrual blood samples 
are strongly correlated with both the blood markers and menstrual blood markers. 
The blood samples are not strongly correlated with the blood markers in the plot 
of components 1 and 2, indicating the blood markers do not explain the variance 
of the blood samples. For both the MiSeq/FGx and the PGM data, the blood and 
menstrual blood markers are difficult to separate with the first two components, 
while the two marker types are negatively correlated in the plot for the third and 
fourth component. The first two components together explain 46% of the variance 
in the MiSeq/FGx data and 56% in the PGM/S5 data, while the third and fourth 
component together explain 20 % and 24 %, respectively.  
Figure 4 shows score plots for the first four PLS components for the MiSeq data, 
including the single source samples used for the model and the predicted scores 
for the four mixture samples (semen-vaginal secretion, blood-saliva, semen-
menstrual blood, saliva-skin). There are seven replicates of each sample since 
there were seven laboratories. The left plot (components 1 and 2) shows distinct 
groupings of semen and saliva samples. In the right plot (components 3 and 4) 
especially the vaginal samples are distinctly grouped. The blood-saliva mixtures 
cluster more towards the saliva samples for components 1 and 2, while for 
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components 3 and 4 they are somewhat more correlated with the blood samples. 
The saliva-skin samples show similar tendencies, clustering with saliva samples 
in the left plot and more with skin samples in the right plot, however the replicates 
look more spread. The semen-vaginal secretion samples are positioned more 
midway between the semen and vaginal samples in the left plot, while they 
cluster with the vaginal secretion samples in the right plot. The semen-menstrual 
blood samples cluster somewhere between semen and menstrual blood for 
components 1 and 2, and are closer to the menstrual blood samples for 
components 3 and 4. 
The same score plots were produced for the first four PLS components for the 
PGM/S5 data, including the single source samples used for the model and the 
predicted scores for the mixture sample, semen-vaginal secretion (Figure 5). 
There are nine replicates of each sample since there were nine laboratories. The 
plots show less clear groupings than the MiSeq/FGx data (Figure 4). Saliva is 
most easy to separate from the rest for components 1 and 2 (left), while the 
remaining samples are more overlapping. Blood and menstrual blood samples 
are especially difficult to separate. For component 3 and 4, blood and menstrual 
blood can be separated, and the vaginal secretion samples show more 
separation from the rest. The semen-vaginal mixture samples cluster more with 
semen samples in the left plot, and more towards the vaginal secretion samples 
in the right plot.  
Figure 6 shows the average read counts obtained by the 7 MiSeq/FGx 
laboratories in the MiSeq/FGX data mixture samples. The mixtures semen-
vaginal secretion, blood-saliva, semen-menstrual blood and saliva-skin are 
presented in separate rows. The known body fluids present in each mixture show 
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high read counts. The standard error on each bar reflects the quite large 
variations observed among laboratories. Figure 7 shows the average read counts 
obtained by the 9 IonTorrent laboratories in the PGM/S5 data mixture sample, the 
same vaginal-semen mixture as in the MiSeq/FGx sample set. Mainly semen and 
vaginal markers show high reads, even higher than for the corresponding sample 
in the MiSeq/FGx data. 
Table S2 lists the additional stains which were analysed by the MiSeq/FGx 
laboratories. Figure 8 shows the corresponding score plots for the first four PLS 
components for the MiSeq/FGx data. The provided samples were included in the 
model, while the laboratories’ own samples were predicted. The laboratories’ own 
samples differ a little from the provided samples; some of them were mock 
casework samples with lower amounts of body fluids being analysed and 
substrates other than cotton swabs being used (e.g. Kleenex, FTA® card and 
panty liner). The additional blood and saliva samples cluster well within the 
pristine blood and saliva samples but are nevertheless distinct even within each 
of the pristine sample groupings. Prediction of semen samples appear to be 
better for components 1 and 2 than for 3 and 4. The same can be observed for 
vaginal secretion samples. The additional menstrual blood samples are rather 
randomly spread for all 4 components at the edge of the menstrual blood cluster. 
Skin samples show a similar pattern for components 1 and 2 as well as for 3 and 
4. For mixed stains, blood-saliva samples tend to cluster more with saliva 
samples in both plots. Semen-vaginal secretion samples are positioned between 
semen and vaginal secretion samples. Blood-vaginal secretion samples cluster 
more with vaginal secretion samples in both plots. In addition, there are some 
samples with body fluids not included in the model, namely nasal secretion and 
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urine. All three samples are positioned randomly and not within specific groups, 
with even the two urine samples being far apart from each other in both score 
plots. 
 
4. Discussion 
In a previous study we presented an assay for targeted mRNA sequencing for the 
identification of human body fluids, optimised for the MiSeq/FGx MPS platform 
[27]. To encourage other laboratories not having access to a MiSeq/FGx platform 
to participate, an ad hoc in-house PGM/S5 assay was developed for this study. 
The purpose of this study was to implement and evaluate the MPS application in 
an extended group. We organised a collaborative exercise within 17 
EUROFORGEN and EDNAP laboratories to test the platform-specific assays. 
The samples and primers were in transit / kept at room temperature for up to 3 
weeks. There was no indication that the temporary non-ideal storage of the 
primer pools at ambient temperature had a detrimental effect on primer 
performance. 
The 17 laboratories analysed 8 (PGM/S5 system) or 24 samples (MiSeq/FGx 
system). The conditions of the prepared stains that were provided by the 
organising laboratory were ideal, i.e. they were relatively fresh (1-2 months from 
preparation to shipment), prepared and stored under laboratory conditions (i.e. 
room temperature, stored in the dark), and in forensic terms relatively large 
amounts of body fluids were used (e.g. 50 µL of blood, saliva, semen). However, 
casework samples are usually compromised and/or old and therefore can be 
insufficient in terms of RNA quality and quantity as was observed with some of 
the additional samples the laboratories analysed. In further experiments, mock 
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and real casework samples will be included to assess more systematically the 
performance of the application to cope with old, degraded and compromised 
samples. 
Most of the laboratories had previous experience with mRNA analyses from 
former collaborative exercises [22-26, 30] and some prior knowledge of 
MiSeq/FGx / PGM/S5 library preparation procedures. The laboratories applied 
their preferred RNA extraction methods, but all further steps were performed 
according to our provided protocols. The library preparation protocols of the 
assays are straightforward, although the PGM/S5 workflow (except for protocols 
including the Ion Chef™ robot) is more time-consuming and requires more 
hands-on experience (e.g. chip loading) than the MiSeq/FGx workflow.  
The manual organic RNA extraction that was recommended by the organising 
laboratory is a simple and cheap method providing higher RNA yields than silica-
column based kit extractions (based on our own experience). This was confirmed 
as laboratories using the organic RNA extraction recovered considerably higher 
RNA concentrations and correspondingly higher read counts. However, if DNA 
has to be analysed in parallel from a casework sample, different extraction 
methods allowing RNA and DNA to be recovered from the same sample have to 
be applied. 
The RNA quantification methods NanoDrop™ and Qubit™ are not very specific 
and sensitive. For Qubit™ the lower detection limit was reached especially for 
blood, semen and skin. NanoDrop™, which is based on a spectrophotometric 
measurement, rather overestimated the actual RNA quantities since residual DNA 
and other contaminants, also absorbing light at 280 nm, are quantified as well. 
One laboratory using NanoDrop™ did take this into account and used the 
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proposed input volumes for library preparation instead of relying on NanoDrop™ 
results. Quantus™ and Quant-iT™ Ribogreen were more sensitive compared to 
Qubit™ and were able to quantify even the low input samples. 
Both RNA extraction and quantification are important steps for forensic RNA 
analyses, especially for sequencing applications where sufficient input amounts 
are pivotal for optimal assay performance. Nevertheless, for some body fluids 
(e.g. blood, semen and skin), despite the ideal and high input RNA stains and the 
use of a manual organic RNA extraction method, the desired input amount of 50 
ng could not be reached. Therefore, extraction methods with maximal yields as 
well as specific and sensitive quantification methods are essential. 
The results of three laboratories had to be excluded from final evaluation, 
because of no or non-specific reads. Two of the laboratories did not use the RT 
enzyme which is part of the library preparation protocol. For the reverse 
transcription reaction several brands of RT enzymes might work. However, some 
incompatibilities of buffers or other reagents from these RT reactions may have 
had a negative influence on subsequent steps of library preparation. For the third 
laboratory we could not find an explanation for the poor results. 
The results from 7 MiSeq/FGx and 9 PGM/S5 laboratories were used for the final 
evaluation. Both marker sets (MiSeq/FGx and PGM/S5) demonstrated moderate 
to high read counts in the body fluid or tissue of interest with little to no counts in 
non-target body fluids. The PGM/S5 workflow seemed to be less reliable with low 
input samples, e.g. blood, semen or skin, in that only manually extracted samples 
resulting in higher RNA yields showed a meaningful result. Although 27 markers 
are shared in both workflows, the choice of the respective amplicons and the 
corresponding primer design are different. This can lead to inconsistent results 
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when the same RNA is analysed with the two different panels (Figure 1). There 
was some inter-laboratory variability in read counts, especially for skin and 
vaginal secretion samples, but overall the results of the laboratories were 
consistent, highly expressed markers showed higher and less expressed markers 
lower read counts. Due to the relatedness of some body fluids that are detected 
with the presented assays, some cross reaction reads for some markers were not 
surprising. For example, markers for vaginal secretion could sporadically be 
observed also in saliva samples since both body fluids are produced by mucous, 
epithelial cells. To visualise the complex data, we performed a PLS analysis, 
where blood, menstrual blood, saliva, semen and vaginal secretion markers and 
samples clustered nicely, although better for MiSeq/FGx than for PGM/S5 data. 
This reflects the issues with low RNA inputs that could be observed for the 
PGM/S5 workflow, resulting in few or no specific reads. Skin samples in particular 
are difficult in several regards. Usually, RNA yields are very low for contact stains. 
In addition, there was mainly one skin marker (LCE1C) that seemed to be 
sensitive enough to be detected in skin samples. 
The score plots of the mixed samples showed that they do not cluster exactly in 
between the two involved body fluids but rather with one of them, depending on 
the type of mixture. This pattern could also be observed using average read 
counts, where one of the two body fluids was dominant, leading to a higher 
coverage than for the other body fluid / tissue. The dominant body fluid in 
mixtures (e.g. vaginal secretion in semen-vaginal secretion mixtures or menstrual 
blood in semen-menstrual blood mixtures) was usually the body fluid that also 
had higher RNA yields in single stains. It is therefore important that for mixtures 
containing body fluids with usually low RNA amounts, e.g. from blood, semen, 
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skin, the latter are not missed due to overrepresentation of the dominant body 
fluid. Future experiments will particularly need to analyse mixed samples 
comprised of variable ratios of these body fluids. 
The additional samples that were tested by laboratories using MiSeq/FGx better 
represented real casework or low input samples. They generally clustered with 
other additional stains of the same body fluid, but sometimes separately within 
the clusters of the pristine, provided stains of the respective body fluid. This 
observation suggests that ideal stains do not reflect the variability of real, 
casework stains. Further analyses should therefore include more casework-like 
samples. In addition, body fluid samples that were not included in the panels 
(urine, nasal secretion) clustered completely randomly, which implies that the 
chosen markers are not suitable, but were also not designed to detect these 
types of body fluids. 
The presented prototype assays and the corresponding results from the 
participating laboratories will serve as a basis for improvements regarding marker 
selection, library preparation and sequencing. Our results suggest that the 
analysis of mRNA by targeting body fluid / tissue specific amplicons is a 
promising tool for body fluid identification. Future developments of the current 
assay will employ coding region SNPs (cSNPs) within the tissue specific genes 
that vary considerably within individuals. In this way we will be able to assign a 
body fluid to a specific individual in mixed donor stains. This will be the task for a 
second collaborative exercise within the same laboratories. 
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Figure captions 
Figure 1: Comparison of results generated on the MiSeq/FGx and PGM/S5. The 
RNA from one sample per body fluid (analysed by laboratory 6) was run on both 
platforms. The reads of the markers (black bars = MiSeq/FGx, grey bars = 
PGM/S5) are displayed as percentage of total reads per sample. Only markers 
which are included in both panels (n=27) are displayed. For menstrual blood 
samples, reads from blood and vaginal secretion are also expected. 
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Figure 2: Interlab comparison for MiSeq/FGx and PGM/S5. The first row shows 
the number of reads per blood marker from all blood samples in relation to the 
read counts sum of all blood markers, from MiSeq/FGx laboratories (left) and 
PGM/S5 laboratories (right). The following rows show the same for semen, saliva, 
vaginal secretion, menstrual blood and skin. Non-specific reads are not 
accounted for in this figure. Not all markers in MiSeq/FGx are represented in 
PGM/S5 and vice versa (see Table 1). 
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Figure 3: PLS correlation loading plots for the first four components for the 
MiSeq/FGx and PGM/S5 data show correlation between the markers and the 
components, and how different body fluid categories (black text) correlate with the 
markers. Markers further away from the origin are more influential on the 
components. The markers are colour coded as red=blood, yellow=semen, 
blue=saliva, green=vaginal secretion, purple=menstrual blood, nude=skin. 
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Figure 4: Score plots for the first four PLS components for the MiSeq/FGx data. 
The single colour circles are the single source samples included in the model. 
The two-coloured circles are the predicted scores for the four mixture samples, 
where the colours represent their mixture composition.  
 
Figure 5: Score plots for the first four PLS components for the PGM/S5 data. The 
single colour circles are the single source samples included in the model. The 
two-coloured circles are the predicted scores for the mixture sample, semen-
vaginal secretion. 
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Figure 6: Average read counts for the MiSeq/FGx data mixture samples. Each 
row represents a mixture of two body fluids / tissues, specified on the right side. 
The standard error on each bar shows the variation per marker among 
laboratories.  
 
Figure 7: Average read counts for the PGM/S5 data mixture sample. The 
standard error on each bar shows the variation per marker among laboratories. 
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Figure 8: Score plots for the first four PLS components for the MiSeq/FGx data, 
with predicted scores for the laboratories’ own samples. The circles represent 
samples included in the model, while the triangles represent the laboratories’ own 
samples (cp. Table S2). 
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Tables 
Table 1: Markers included in the TruSeq Targeted RNA Expression panel 
(MiSeq/FGx) detecting 33 body fluid specific transcripts and in the Ion 
AmpliSeq™ RNA custom panel (PGM/S5) detecting 29 body fluid specific 
transcripts. 
Body fluid/tissue Gene 
MiSeq/FGx PGM/S5 
33plex 29plex 
Blood 
ALAS2     
ANK1     
SPTB     
CD3G     
CD93     
AMICA1     
Semen 
PRM1     
PRM2     
TGM4     
SEMG1     
SEMG2     
KLK3     
Saliva 
HTN3     
HTN1     
STATH     
PRB3     
PRB4     
PRH2     
PRB1     
MUC7     
Vaginal 
CYP2B7P1     
DKK4     
FAM83D     
CYP2A6     
Menstrual 
MMP10     
LEFTY2     
MMP7     
MMP11     
SFRP4     
Skin 
LCE1C     
CCL27     
IL37     
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SERPINA12     
KRT77     
COL17A1     
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Table 2: RNA extraction and quantification methods used by the participating laboratories. Results of RNA quantification are listed 
for the provided stains 11-28. Results from manual extractions are highlighted in green. nd = not detected. 
[ng/µL] 
extraction 
method 
quantification 
method 
11 12 13 14 15 16 17 18 19 20 21 22/23 24 25 26 27/28 
Lab_1 Kit Qubit nd nd nd nd 16.5 24.6 4 nd 23.2 71 29.4 nd 128 6.1 31.4 nd 
Lab_2 Kit Qubit nd nd nd nd 2.63 3.05 nd nd 2.3 nd 4.76 nd 20.5 nd 11.5 nd 
Lab_3 Kit NanoDrop 3.8 4 2.2 2.1 30.1 130.4 15.4 3.9 62.2 86.9 39.6 2.7 127.2 10.9 30.1 7.2 
Lab_4 Kit Qubit - - - - - - - - - - - - - - - - 
Lab_5 Kit Qubit <0.5 0.81 1.04 0.76 4.44 15.2 2.17 1.22 9.19 44.6 9.63 0.5 >60 0.69 51 0.87 
Lab_6 manual Quantus 29.35 34.6 43.3 57.25 26.9 190 24 61 259.5 234.5 69.6 11 377.5 74.85 212.5 36.9 
Lab_7 manual 
Quant-iT 
RiboGreen 
23 25.2 64.3 79.9 18 119 33.7 68.2 334.8 471.3 44.7 nd 525 50 392.4 16.6 
Lab_8 Kit no quant - - - - - - - - - - - - - - - - 
Lab_9 Kit Qubit nd nd nd nd 10 10 nd nd 3.3 9.7 2.7 nd 32 nd 21.5 nd 
Lab_10 Kit no quant   -     - - -   -   - - -       
Lab_11 Kit no quant   -     - - -   -   - - -       
Lab_12 Kit Qubit/NanoDrop*   4.8     5.5 8 3.8*   11.6   4.4 4.7* 9.6       
Lab_13 Kit Qubit   nd     nd 56 nd   12.9   9.02 nd 54.8       
Lab_14 manual Qubit   16.2     8.2 15.6 5.6   65   39.3 2.4 129       
Lab_15 manual NanoDrop   117.7     223 143.7 107.7   436   107.7 66.25 477.4       
Lab_16 manual Qubit   nd     2 10.2 2.1   43.6   8.12 nd 33.6       
Lab_17 Kit no quant - - - - - - - - - - - - - - - - 
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Table 3: Body fluid inference displaying mean percent contributions for the six body fluid categories (BL = blood, SE = semen, SA = 
saliva, VS = vaginal secretion, MB = menstrual blood, SK = skin), resulting conclusions and actual components of stains (16 stains 
from 7 labs using MiSeq/FGx and 8 stains from 9 labs using PGM/S5). Samples with <5000 total reads were excluded (column 
“used data”). SD = standard deviation. 
Mean Percent Contribution (SD) 
stain used data BL SE SA VS MB SK conclusion actual 
11 7/7 92 (8) 2 (3) 3 (7) 3 (4) 0 (1) 0 (0) BL BL 
12 7/7 98 (4) 0 (1) 1 (2) 0 (0) 0 (0) 1 (1) BL BL 
12 PGM/S5 3/9 100 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) BL BL 
13 4/7 90 (10) 0 (0) 2 (2) 6 (10) 2 (1) 0 (0) BL BL 
14 4/7 95 (4) 2 (2) 3 (5) 0 (0) 0 (0) 1 (1) BL BL 
15 7/7 8 (8) 2 (3) 87 (12) 1 (2) 0 (0) 2 (5) SA SA 
15 PGM/S5 3/9 0 (0) 0 (0) 86 (19) 14 (19) 0 (0) 0 (0) SA (+VS?) SA 
16 7/7 5 (4) 2 (4) 69 (31) 18 (23) 5 (13) 2 (4) SA (+VS?) SA 
16 PGM/S5 4/9 0 (1) 0 (0) 72 (20) 27 (21) 0 (0) 0 (0) SA (+VS?) SA 
17 7/7 0 (1) 98 (4) 1 (3) 0 (0) 0 (0) 0 (1) SE SE 
17 PGM/S5 4/9 0 (0) 100 (0) 0 (0) 0 (0) 0 (0) 0 (0) SE SE 
18 7/7 0 (0) 100 (1) 0 (0) 0 (0) 0 (0) 0 (0) SE azoosp SE azoosp 
19 6/7 9 (4) 3 (5) 7 (17) 78 (25) 0 (0) 2 (5) VS VS 
19 PGM/S5 7/9 0 (0) 1 (2) 0 (0) 98 (2) 1 (1) 0 (1) VS VS 
20 5/7 1 (1) 5 (7) 3 (5) 25 (10) 64 (20) 3 (4) MB MB 
21 6/7 13 (6) 1 (3) 3 (7) 0 (0) 81 (13) 1 (3) MB MB 
21 PGM/S5 6/9 24 (8) 0 (0) 0 (0) 1 (1) 74 (10) 1 (1) MB MB 
22/23 2/7 1 (0) 1 (0) 0 (0) 0 (0) 1 (1) 97 (2) SK SK 
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22/23 PGM/S5 0/9 - - - - - - - SK 
24 7/7 7 (7) 26 (13) 2 (6) 57 (18) 0 (0) 7 (5) VS / SE VS / SE 
24 PGM/S5 8/9 0 (0) 32 (17) 0 (0) 67 (18) 0 (0) 1 (1) VS / SE VS / SE 
25 5/7 27 (14) 2 (3) 69 (14) 0 (0) 0 (0) 2 (4) BL / SA BL / SA 
26 7/7 4 (2) 26 (7) 0 (1) 8 (3) 61 (8) 0 (0) MB / SE MB / SE 
27/28 6/7 7 (5) 3 (3) 75 (12) 1 (1) 0 (1) 14 (11) SK / SA SK / SA 
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